Lumican modulates adipocyte function in obesity-associated type 2 diabetes
Date
2022Author
Strieder-Barboza, Clarissa (TTU)
Flesher, Carmen G
Geletka, Lynn M
Eichler, Tad
Akinleye, Olukemi
Ky, Alexander
Ehlers, Anne P
Lumeng, Carey N
O’Rourke, Robert W
Metadata
Show full item recordAbstract
Obesity-associated type 2 diabetes (DM) leads to adipose tissue dysfunction. Lumican is a proteoglycan implicated in obesity, insulin resistance (IR), and adipocyte dysfunction. Using human visceral adipose tissue (VAT) from subjects with and without DM, we studied lumican effects on adipocyte function. Lumican was increased in VAT and adipocytes in DM. Lumican knockdown in adipocytes decreased lipolysis and improved adipogenesis and insulin sensitivity in VAT adipocytes in DM, while treatment with human recombinant lumican increased lipolysis and impaired insulin-sensitivity in an ERK-dependent manner. We demonstrate that lumican impairs adipocyte metabolism, partially via ERK signalling, and is a potential target for developing adipose tissue-targeted therapeutics in DM.